Selected article for: "aberrant inflammation and acute ards respiratory distress syndrome"
Author: Rezakhani, Leila; Kelishadrokhi, Ali Fatahian; Soleimanizadeh, Arghavan; rahmati, Shima
Title: Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for Patients Infected with COVID-19: Real Opportunities and Range of Promises
  • Cord-id: 7a04kx5n
  • Document date: 2020_11_12
    • ID: 7a04kx5n
    Snippet: There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesench
    Document: There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesenchymal stem cells and their derivatives can suppress inflammation. Exosomes function as intercellular communication vehicles to transfer bioactive molecules (based on their origins), between cells. In this review, the recent exosome-based clinical trials for the treatment of COVID-19 are presented. Potential therapy may include the following items: First, using mesenchymal stem cells secretome. Second, incorporating specific miRNAs and mRNAs into exosomes and last, using exosomes as carriers to deliver drugs.

    Search related documents:
    Co phrase search for related documents
    • acute ali lung injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ali lung injury and lung disease treatment: 1
    • acute ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ali lung injury and lung repair: 1, 2, 3
    • acute ards respiratory distress syndrome and admission ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low specificity: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung disease treatment: 1, 2, 3
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission ratio and long term outcome: 1
    • admission ratio and lung disease: 1, 2, 3
    • admission ratio and lung injury: 1, 2, 3
    • long distance and low chance: 1
    • long term outcome and lung disease: 1, 2, 3
    • long term outcome and lung disease treatment: 1
    • long term outcome and lung injury: 1, 2, 3
    • low specificity and lung disease: 1, 2, 3, 4, 5, 6